-+ 0.00%
-+ 0.00%
-+ 0.00%

Adocia says Phase 3 China study shows BioChaperone Lispro improves postprandial glucose vs lispro

PUBT·09/17/2026 16:03:09
Listen to the news
Adocia says Phase 3 China study shows BioChaperone Lispro improves postprandial glucose vs lispro
  • Adocia flagged upcoming disclosures from a Phase 3 trial of BioChaperone Lispro in type 2 diabetes patients in China.
  • Full results will be presented at the EASD Annual Meeting in Milan on September 29, 2026.
  • Management framed the readout as showing better post-meal control and overall daily glucose control versus standard lispro.
  • Separate AdoShell islet-transplant work will be presented at EASD on October 2, 2026, supporting scalability toward human use.
  • Additional preclinical AdoShell data targeting immunosuppression-free islet replacement is scheduled for the Breakthrough T1D congress on October 11, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adocia SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609171200BIZWIRE_USPR_____20260917_BW588866) on September 17, 2026, and is solely responsible for the information contained therein.